Agalsidase beta



Drug updated on 12/19/2023

Dosage FormInjection (intravenous: 5 mg, 35mg)
Drug ClassHydrolytic lysosomal neutral glycosphingolipid-specific enzyme
Ongoing and
Completed Studies


  • For the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Fabrazyme (agalsidase beta) Prescribing Information.2023Genzyme Corporation, Cambridge, MA

Randomized Controlled Trials